Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

Specimen Handling 655pembrolizumab 605Magnetic Resonance Spectroscopy 562Carboplatin 445Cisplatin 396Cyclophosphamide 394Biopsy 378Nivolumab 323Paclitaxel 320Gemcitabine 313Radiotherapy 293Bevacizumab 248Dexamethasone 221fludarabine 212Docetaxel 201durvalumab 193atezolizumab 186Oxaliplatin 186venetoclax 182Fluorouracil 175Rituximab 173Pemetrexed 172Capecitabine 170Radiation 166Doxorubicin 166Radiosurgery 158Ipilimumab 145Etoposide 142Leucovorin 140Lenalidomide 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hizentra × 90 days × Clear all
NCT07582432 2026-05-12

SIGMA

Grifols Biologicals, LLC

Phase 3 Recruiting
49 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡